La Dra. Silvia Valbuena López repasa los resultados del estudio con ticagrelor y prasugrel en pacientes con síndrome coronario agudo, presentado en ESC Congress 2019.
Call Girls Jaipur Just Call 9521753030 Top Class Call Girl Service Available
ISAR REACT Study
1. Silvia Valbuena López
ISAR-REACT 5:
TICAGRELOR VS PRASUGREL
IN ACUTE CORONARY SYNDROMES
NEJM. September 1, 2019. DOI: 10.1056/NEJMoa1908973
2. Silvia Valbuena LópezISAR-REACT 5
BACKGROUND
• PLATO and TRITON-TIMI trials showed superiority of ticagrelor and prasugrel compared to
clopidogrel in ACS
• No trial to date has directly evaluated both drugs
NON-STEMI STEMI
3. Silvia Valbuena LópezISAR-REACT 5
AIM head to head comparison of a Ticagrelor vs Prasugrel-based
strategy in ACS patients with/without ST-elevation
HYPOTHESIS Ticagrelor will be superior to Prasugrel (expected
incidence of primary endpoint 10% vs 12,9%, RRR 22,5%)
4. Silvia Valbuena LópezISAR-REACT 5
TRIAL DESIGN
• Investigator-led (DZHK München)
• Randomized, multicenter, open-label
• Outcomes asigned by blinded evaluator
• Inclusion ACS with planned invasive strategy
• Endpoints:
- Primary endpoint death + MI + stroke (12 months)
- Secondary endpoint death, MI, stroke, stent thrombosis (definite or probable)
- Safety endpoint Bleeding BARC 3-5
• Ticagrelor and Prasugrel doses as per guidelines Prasugrel administered after
angiography in N-STEMI
12. Silvia Valbuena LópezISAR-REACT 5
CONCLUSIONS
In patients with ACS with or without ST-elevation, Prasugrel
compared to Ticagrelor significantly reduced the composite
endpoint of death, MI or stroke